Life-threatening
graft-versus-host disease (GVHD) limits the use of
HLA-C-mismatched unrelated donors in
transplantation. Clinicians lack criteria for
donor selection when
HLA-C-mismatched donors are a patient's only option for cure. We examined the role for
HLA-C expression levels to identify permissible
HLA-C mismatches. The median fluorescence intensity, a proxy of
HLA-C expression, was assigned to each
HLA-C allotype in 1975 patients and their
HLA-C-mismatched unrelated transplant donors. The association of outcome with the level of expression of patients' and donors'
HLA-C allotypes was evaluated in multivariable models. Increasing expression level of the patient's mismatched
HLA-C allotype was associated with increased risks of grades III to IV acute GVHD, nonrelapse mortality, and mortality. Increasing expression level among
HLA-C mismatches with residue 116 or residue 77/80 mismatching was associated with increased nonrelapse mortality. The immunogenicity of
HLA-C mismatches in unrelated donor
transplantation is influenced by the expression level of the patient's mismatched
HLA-C allotype.
HLA-C expression levels provide new information on mismatches that should be avoided and extend understanding of
HLA-C-mediated immune responses in human disease.